Mira Pharmaceuticals Inc (MIRA)

NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-23

$0.62-1.49%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Mira Pharmaceuticals Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.03
Annual ending 2026-12-31
Revenue	—	276M
EPS	—	-0.12
Annual ending 2027-12-31
Revenue	—	40M
EPS	—	-0.16

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce losses and improve EPS trajectory	A supporting condition in Mira Pharmaceuticals Inc's published investment case. The stated target is EPS loss narrows from -$0.41 toward break-even.	Broken	EPS remains below -$0.41 or worsens next fiscal year	Diluted EPS: $-0.03 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$0.41 toward break-even. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-0.03 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9a00b912-5e96-4b52-a98f-02c91d2ef9ef. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize executive leadership after CFO departure	Despite losses, management is improving execution amid volatile CFO changes.	Under Pressure	continued executive turnover or no CFO replacement within 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance clinical development of MIRA-55 and SKNY-1	MIRA Pharmaceuticals advances its drug pipeline with exclusive rights for MIRA-55 and SKNY-1.	Improving	failure to initiate Phase 2a trial or loss of exclusive rights within next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	0 / 1
2026-07-25	Unavailable	Unavailable	0 / 1
2026-07-26	Unavailable	Unavailable	0 / 1
2026-07-27	Unavailable	Unavailable	0 / 1
2026-07-28	Unavailable	Unavailable	0 / 1
2026-07-29	Unavailable	Unavailable	0 / 1
2026-07-30	Unavailable	Unavailable	0 / 1
2026-07-31	Unavailable	Unavailable	0 / 1
2026-08-01	Unavailable	Unavailable	0 / 1
2026-08-02	Unavailable	Unavailable	0 / 1
2026-08-03	Unavailable	Unavailable	0 / 1
2026-08-04	Unavailable	Unavailable	0 / 1
2026-08-05	Unavailable	Unavailable	0 / 1
2026-08-06	Unavailable	Unavailable	0 / 1
2026-08-07	Unavailable	Unavailable	0 / 1
2026-08-08	Unavailable	Unavailable	0 / 1
2026-08-09	Unavailable	Unavailable	0 / 1
2026-08-10	Unavailable	Unavailable	0 / 1
2026-08-12	Unavailable	Unavailable	0 / 1
2026-08-13	Unavailable	Unavailable	0 / 1
2026-08-14	Unavailable	Unavailable	0 / 1
2026-08-15	Unavailable	Unavailable	0 / 1
2026-08-16	Unavailable	Unavailable	0 / 1
2026-08-17	Unavailable	Unavailable	0 / 1
2026-08-18	Unavailable	Unavailable	0 / 1
2026-08-19	Unavailable	Unavailable	0 / 1
2026-08-20	Unavailable	Unavailable	0 / 1
2026-08-21	Unavailable	Unavailable	0 / 1
2026-08-22	Unavailable	Unavailable	0 / 1
2026-08-23	Unavailable	Unavailable	0 / 1
2026-08-24	Unavailable	Unavailable	0 / 1
2026-08-25	Unavailable	Unavailable	0 / 1
2026-08-26	Unavailable	Unavailable	0 / 1
2026-08-27	Unavailable	Unavailable	0 / 1
2026-08-28	Unavailable	Unavailable	0 / 1
2026-08-29	Unavailable	Unavailable	0 / 1
2026-08-30	Unavailable	Unavailable	0 / 1
2026-08-31	Unavailable	Unavailable	0 / 1
2026-09-01	Unavailable	Unavailable	0 / 1
2026-09-02	Unavailable	Unavailable	0 / 1
2026-09-03	Unavailable	Unavailable	0 / 1
2026-09-04	Unavailable	Unavailable	0 / 1
2026-09-05	Unavailable	Unavailable	0 / 1
2026-09-06	Unavailable	Unavailable	0 / 1
2026-09-07	Unavailable	Unavailable	0 / 1
2026-09-08	Unavailable	Unavailable	0 / 1
2026-09-09	Unavailable	Unavailable	0 / 1
2026-09-10	Unavailable	Unavailable	0 / 1
2026-09-11	Unavailable	Unavailable	0 / 1
2026-09-12	Unavailable	Unavailable	0 / 1
2026-09-13	Unavailable	Unavailable	0 / 1
2026-09-14	Unavailable	Unavailable	0 / 1
2026-09-15	Unavailable	Unavailable	0 / 1
2026-09-16	Unavailable	Unavailable	0 / 1
2026-09-17	Unavailable	Unavailable	0 / 1
2026-09-18	Unavailable	Unavailable	0 / 1
2026-09-19	Unavailable	Unavailable	0 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-09-01	1	0	0
2026-10-01	1	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce losses and improve EPS trajectoryPublished status: Broken
Stabilize executive leadership after CFO departurePublished status: Under Pressure
Advance clinical development of MIRA-55 and SKNY-1Direct metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-63.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Mira Pharmaceuticals Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative development-stage biotech, not an established earnings compounder. The long-term thesis is still insufficiently clear because the company has no reported revenue, remains loss-making, and has limited clinical execution evidence.

What's priced into Mira Pharmaceuticals Inc

The evidence snapshot provides no valuation measure or direct account of market expectations, so whether MIRA is cheap or expensive versus peers cannot be assessed. The shares have reacted negatively, but the evidence does not show what expectations are already reflected.

What the fundamentals likely do

Near term, losses and no revenue are likely to remain central while the company advances its drug programs. MIRA-55 has encouraging preclinical findings, SKNY-1 has a dose-selection milestone, and Ketamir-2 has a Phase 2a protocol submitted for review, but clinical-stage progress remains unproven. Recent litigation filings and a missed quarter add near-term uncertainty.

What Mira Pharmaceuticals Inc hinges on

Over the multi-year view, the key test is whether preclinical progress turns into clinical-stage advancement across the programs. Near-term sentiment also depends on whether healthcare-sector support continues; weakening jobs data or poorer results and guidance from sector bellwethers could weaken that tailwind. Further litigation developments are another risk to monitor.